Phase I trial of docetaxel and vinorelbine in patients with advanced nonsmall cell lung carcinoma Academic Article Article uri icon

Overview

MeSH Major

  • Carcinoma, Squamous Cell
  • Combined Modality Therapy
  • Head and Neck Neoplasms
  • Maximum Tolerated Dose

abstract

  • Docetaxel at a dose of 60 mg/m(2) and vinorelbine at a dose of 45 mg/m(2), both given every 2 weeks, can be combined safely to achieve Phase II dose intensity of both agents. An ongoing Phase II trial will define the activity of this treatment combination.

publication date

  • March 2000

Research

keywords

  • Academic Article

Identity

Digital Object Identifier (DOI)

  • 10.1002/(SICI)1097-0142(20000301)88:5<1045::AID-CNCR14>3.0.CO;2-J

PubMed ID

  • 10699893

Additional Document Info

start page

  • 1045

end page

  • 50

volume

  • 88

number

  • 5